Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RPA1 | P27694 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984616 | 0.92 | CYP1A2 (0.46) | CYP1A2HIF1ASMN1; SMN2PPP1CACNR1 | |
| SCHEMBL1983441 | 0.89 | CYP1A2 (0.45) | CYP1A2HIF1ASMN1; SMN2PPP1CACNR1 | |
| SCHEMBL1987131 | 0.86 | MAPT (0.42) | CYP1A2HIF1ASMN1; SMN2PPP1CACNR1 | |
| SCHEMBL1982830 | 0.86 | MAPT (0.49) | ALDH1A1RPA1MAPTAPPKDM4E | |
| SCHEMBL1987372 | 0.85 | CNR2 (0.53) | CNR1CNR2 | |
| SCHEMBL1986572 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2PPP1CACNR1RPA1MAPT | |
| SCHEMBL1984826 | 0.82 | MAPT (0.47) | CYP1A2PTGS2ALDH1A1RPA1MAPT | |
| SCHEMBL1983556 | 0.81 | CYP1A2 (0.48) | CYP1A2HIF1ASMN1; SMN2PPP1CACNR1 | |
| SCHEMBL1985488 | 0.81 | CNR1 (0.50) | CYP1A2HIF1ASMN1; SMN2PPP1CACNR1 | |
| SCHEMBL277784 | 0.79 | CNR1 (0.62) | CYP1A2HIF1ASMN1; SMN2PPP1CACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1602656-B1 | PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2011-06-29 | — | — | EP | claimed |
| EP-1602656-A1 | PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS | NEUROSCIENZE PHARMANESS S.C. a R.L. (IT) | 2005-12-07 | — | — | EP | claimed |
| US-20050261281-A1 | Pharmaceutical compounds | MIDCAP FUNDING III, LLC | 2005-11-24 | — | — | US | claimed |
| US-8227620-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2012-07-24 | — | — | US | disclosed |
| EP-1602656-B1 | PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2011-06-29 | — | — | EP | disclosed |
| US-20100105896-A1 | PHARMACEUTICAL COMPOUNDS | Neuroscienze Pharmaness S.C.a.R.I. (IT) | 2010-04-29 | — | — | US | disclosed |
| US-7659407-B2 | pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; immune disorders, osteoporosis, renal ischemia, inflammation,transplant rejection; 5-(5-Chloro-thiofen-2-yl)-1-(4-methoxy-phenyl)-4-methyl-1H-pyrazol-3-carboxylic acid | Neuroscienze Pharmaness S.C.a.R.I. (IT) | 2010-02-09 | — | — | US | disclosed |
| EP-1602656-A1 | PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS | NEUROSCIENZE PHARMANESS S.C. a R.L. (IT) | 2005-12-07 | — | — | EP | disclosed |
| US-20050261281-A1 | Pharmaceutical compounds | MIDCAP FUNDING III, LLC | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105896-A1 | PHARMACEUTICAL COMPOUNDS | CNR1, CNR2, OPRD1 | CYP1A2 129/4885HIF1A 2240/4885SMN1; SMN2 4836/4885 |
| US-20050261281-A1 | Pharmaceutical compounds | CNR1, CNR2, OPRD1 | CYP1A2 207/4885HIF1A 1502/4885SMN1; SMN2 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.